COMMUNIQUÉS West-GlobeNewswire

SnoreRX Anti-Snoring Mouthpiece Claims Evaluated: Doctor-Recommended Adjustable Mouthguard for Safer Airway Breathing Overnight
21/04/2026
SnoreRX examines its FDA-cleared mandibular advancement mouthpiece design, 1-millimeter adjustable calibration, boil-and-bite custom fitting process, 30-day guarantee terms, pricing structure, and what consumers should [...]
Enjoin Launches Technology-First Rebrand For Scalable Revenue Integrity
21/04/2026
Enjoin, a clinically intelligent revenue optimization platform for health systems, announced a refreshed brand identity reflecting continued investment in workflow-driven technology, advanced analytics, and clinical [...]
Moonbuddy Kids Breathing Guidance Under Investigation: Tactile Breathwork Device Claims Get Reviewed
21/04/2026
A 2026 informational overview of Moonbuddy's screen-free calming device for children, slow-paced breathing research context, 4-minute sleep support claims, parasympathetic activation positioning, pricing structure, and [...]
Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
20/04/2026
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced [...]
Regeneron Announces Investor Conference Presentations
20/04/2026
TARRYTOWN, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: • BofA Securities Health Care Conference 2026 at 10:00 a.m. PT (1:00 [...]
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
20/04/2026
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are expected in the second half [...]
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
20/04/2026
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” [...]
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
20/04/2026
MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with [...]
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
20/04/2026
Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage psychedelic biotech company focused on the discovery and development of novel [...]
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering
20/04/2026
WESTFIELD, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the “Company”) announced the closing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary [...]
FibroBiologics Compliant with All Nasdaq Listing Requirements
20/04/2026
HOUSTON, April 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
20/04/2026
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/04/2026
FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase [...]
SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
20/04/2026
SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced [...]
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event
20/04/2026
LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that [...]
Spectral AI Announces Annual Meeting of Stockholders
20/04/2026
DALLAS, April 20, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
20/04/2026
SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
20/04/2026
NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
20/04/2026
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 15, 2026 it granted stock options to purchase an aggregate of 49,358 shares of [...]

Pages